ScholarIQanswers from OpenAlex & ORCID
Karim Fizazi
ResearcherPublications, citations & collaboration network
Karim Fizazi is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Karim Fizazi have?
ScholarIQindexed works
Karim Fizazi has 1,573 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Karim Fizazi have?
ScholarIQcitation count
Karim Fizazi has 85,354 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Karim Fizazi?
ScholarIQh-index
Karim Fizazi has an h-index of 126 in OpenAlex.
What is the i10-index of Karim Fizazi?
ScholarIQi10-index
Karim Fizazi has an i10-index of 536 in OpenAlex.
What is the ORCID of Karim Fizazi?
ScholarIQorcid
The ORCID for Karim Fizazi is on the source record.
What is the OpenAlex record for Karim Fizazi?
ScholarIQopenalex
The OpenAlex for Karim Fizazi is on the source record.
What are the most-cited papers on Karim Fizazi?
ScholarIQmost cited works
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim Fizazi, Fred Saad, Mary‐Ellen Taplin, Cora N. Sternberg, Kurt Miller, Ronald de Wit, Peter F.A. Mulders, Kim N., Neal D. Shore, Andrew J. Armstrong, Thomas W. Flaig, Aude Fléchon, Paul N. Mainwaring, Mark T. Fleming, John D. Hainsworth, Mohammad Hirmand, Bryan Selby, Lynn Seely, Johann S. de Bono
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono, Christopher J. Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N., Robert J. Jones, Oscar B. Goodman, Fred Saad, John Staffurth, Paul N. Mainwaring, Stephen Harland, Thomas W. Flaig, Thomas E. Hutson, Tina Cheng, Helen Patterson, John D. Hainsworth, Charles J. Ryan, Cora N. Sternberg, Susan Ellard, Aude Fléchon, Mansoor N. Saleh, Mark C. Scholz, Eleni Efstathiou, Andrea Zivi, Diletta Bianchini, Yohann Loriot, Nicole Chieffo, Thian Kheoh, Christopher M. Haqq, Howard I. Scher
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf, Yohann Loriot, Cora N. Sternberg, Celestia S. Higano, Peter Iversen, Suman Bhattacharya, Joan Carles, Simon Chowdhury, Ian D. Davis, Johann S. de Bono, Christopher P. Evans, Karim Fizazi, Anthony M. Joshua, Choung‐Soo Kim, Go Kimura, Paul N. Mainwaring, Harry H. Mansbach, Kurt Miller, Sarah B. Noonberg, Frank Perabo, De Phung, Fred Saad, Howard I. Scher, Mary‐Ellen Taplin, Peter Venner, Bertrand Tombal
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan, Matthew R. Smith, Johann S. de Bono, Arturo Molina, Christopher J. Logothetis, Paul de Souza, Karim Fizazi, Paul N. Mainwaring, Josep M. Piulats, Siobhan Ng, Joan Carles, Peter F.A. Mulders, Ethan Basch, Eric J. Small, Fred Saad, Dirk Schrijvers, Hendrik Van Poppel, Som D. Mukherjee, H. Suttmann, Winald R. Gerritsen, Thomas W. Flaig, Daniel J. George, Evan Y. Yu, Eleni Efstathiou, Allan J. Pantuck, Eric Winquist, Celestia S. Higano, Mary-Ellen Taplin, Youn Park, Thian Kheoh, Thomas W. Griffin, Howard I. Scher, Dana E. Rathkopf
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Oliver Sartor, Johann S. de Bono, Kim N., Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Luke T. Nordquist, Nitin Vaishampayan, Ghassan El‐Haddad, Chandler H. Park, Tomasz M. Beer, Alison Armour, Wendy J. Pérez-Contreras, Michelle DeSilvio, Euloge Kpamegan, Germo Gericke, Richard A. Messmann, Michael J. Morris, Bernd J. Krause